Clinical Trials
8 trialsNCT04074096 2026-06-05
BEPCOME-MB
UNICANCER
Phase 2 Active not recruiting
NCT05576896 2026-06-04
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
Northwestern University
Phase 2 Active not recruiting
NCT04017650 2026-05-22
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT05615818 2026-05-19
SAFIR-ABC10
UNICANCER
Phase 3 Recruiting
NCT03803553 2026-05-01
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
Massachusetts General Hospital
Phase 3 Recruiting
NCT07092410 2026-04-21
SuRage-EB
SRH Wald-Klinikum Gera GmbH
Phase 4 Withdrawn
NCT05026983 2026-04-16
Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04061980 2026-04-13
Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer
Providence Health & Services
Phase 2 Active not recruiting